+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032- Product Image
New

Non-small Cell Lung Cancer Therapeutics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968594
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Non-small Cell Lung Cancer Therapeutics Market is entering a new phase of evolution, shaped by innovation in targeted therapies, advancements in diagnostics, and increasingly complex requirements from payers and regulators. These shifts demand proactive strategy and informed decisions from senior industry leaders.

Market Snapshot: Non-small Cell Lung Cancer Therapeutics Market

The Non-small Cell Lung Cancer Therapeutics Market grew from USD 34.98 billion in 2025 to USD 38.26 billion in 2026. With a projected CAGR of 9.75%, the market is expected to reach USD 67.13 billion by 2032. This trajectory underscores a sector redefined by clinical breakthroughs, wider diagnostic utilization, and adaptive commercialization. Heightened competition and demand for differentiated, patient-centric solutions continue to drive transformation among incumbent industry leaders and new entrants alike.

Scope & Segmentation

This report delivers an in-depth assessment of the global NSCLC therapeutics landscape, highlighting the critical factors shaping market opportunities. Segmentation reveals how therapeutic advancements, diagnostics, and innovative commercial strategies increase enterprise value and foster competitive differentiation.

  • Treatment Types: Includes chemotherapy, immunotherapies such as CTLA-4, PD-1, and PD-L1 inhibitors, and targeted treatments—ALK, BRAF, EGFR, and ROS1 inhibitors—each with unique market drivers and adoption profiles.
  • Line of Therapy: Analyzes first-line to further-line applications, exploring key differences in clinical endpoints, launch sequencing, and shifting payer requirements throughout the patient journey.
  • Biomarker Segmentation: Covers ALK rearrangement, EGFR mutation, PD-L1 expression, and KRAS mutation, supporting personalized medicine and companion diagnostic integration.
  • Distribution Channels: Maps out hospital, online, and retail pharmacy channels, with highlights on supply chain resilience, cold-chain management, and expanded patient support services to maximize accessibility and adherence.
  • Geographic Regions: Examines the Americas, Europe, Middle East & Africa, and Asia-Pacific, accounting for distinct regional regulatory timelines, diagnostic readiness, and market access dynamics—emphasizing the need for regionally tailored strategies.
  • Technologies: Studies next-generation sequencing, liquid biopsy, decentralized trial models, and digital patient engagement tools that accelerate trial accrual, evidence-generation, and personalized care delivery.

Key Takeaways for Decision-Makers

  • Integrated approaches now combine drug development, diagnostic validation, and market access, streamlining the path from innovation to clinical adoption while aligning more closely with payer and regulatory demands.
  • Innovative immunotherapy and targeted therapy combinations increasingly require flexible trial designs and robust real-world evidence to secure value-based contracting and formulary inclusion.
  • Regional disparities in regulation and reimbursement necessitate agile, localized strategies to address access barriers, particularly for novel diagnostics and combination regimens.
  • Growth in the sector is closely linked to strategic partnerships, including collaborations with diagnostic firms and contract research organizations to accelerate trial enrollment and expand access to cutting-edge therapies.
  • Stakeholder discussions are progressively shaped by real-world outcomes data, driving the adoption of performance-based agreements and the need for transparent, long-term value demonstration.

Tariff Impact: NSCLC Supply Chains and Market Access

Recent shifts in United States tariff policy are altering the sourcing, cost structure, and security of supply for NSCLC drugs and diagnostics. Fluctuations in duties on active pharmaceutical ingredients and diagnostic kits push organizations to diversify supplier bases, consider nearshoring, and update risk management practices.

  • Procurement now centers on flexible contract terms, increased buffer inventories, and proactive pricing strategies to address evolving tariff conditions.
  • Disruptions in diagnostic availability heighten the need to prioritize domestic test development and seek alternative sources to minimize patient pathway interruptions.
  • Investments in scenario planning and resilient supply chain adaptation aim to safeguard commercial launches, maintain price transparency, and ensure uninterrupted access to innovative treatments.

Methodology & Data Sources

This analysis integrates data from peer-reviewed clinical research, regulatory documents, trial registries, and major scientific conference proceedings. Insights from structured interviews with clinical, regulatory, and supply chain experts enhance context and rigor. Acknowledged limitations include potential delays in dataset updates and ongoing evolution of evidence.

Why This Report Matters

  • Directly connects therapeutic innovation with real-world commercial execution, empowering leadership to optimize investments, prioritize portfolio expansion, and align R&D strategies with evolving market needs.
  • Supports resilience in regulatory navigation, payer engagement, and supply chain continuity within increasingly complex market environments.
  • Enables effective alignment of diagnostic integration, patient pathway optimization, and access planning in pursuit of sustainable NSCLC market leadership.

Conclusion

Competing in the NSCLC therapeutics market requires integrated expertise in science, diagnostics, and commercial strategy. By leveraging this data-driven insight, organizations can position themselves to advance patient access while strengthening adaptable, future-ready market positions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Non-small Cell Lung Cancer Therapeutics Market, by Treatment Type
8.1. Chemotherapy
8.2. Immunotherapy
8.2.1. CTLA-4 Inhibitors
8.2.1.1. Ipilimumab
8.2.2. PD-1 Inhibitors
8.2.2.1. Nivolumab
8.2.2.2. Pembrolizumab
8.2.3. PD-L1 Inhibitors
8.2.3.1. Atezolizumab
8.2.3.2. Avelumab
8.2.3.3. Durvalumab
8.3. Targeted Therapy
8.3.1. ALK Inhibitors
8.3.2. BRAF Inhibitors
8.3.3. EGFR Inhibitors
8.3.3.1. First Generation
8.3.3.2. Second Generation
8.3.3.3. Third Generation
8.3.4. ROS1 Inhibitors
9. Non-small Cell Lung Cancer Therapeutics Market, by Line Of Therapy
9.1. First Line
9.1.1. Chemotherapy
9.1.2. Combination Therapy
9.1.3. Immunotherapy
9.1.4. Targeted Therapy
9.2. Second Line
9.2.1. Chemotherapy
9.2.2. Combination Therapy
9.2.3. Immunotherapy
9.2.4. Targeted Therapy
9.3. Third Or Later
9.3.1. Chemotherapy
9.3.2. Combination Therapy
9.3.3. Immunotherapy
9.3.4. Targeted Therapy
10. Non-small Cell Lung Cancer Therapeutics Market, by Biomarker Expression
10.1. ALK Rearrangement
10.2. EGFR Mutant
10.3. High PD-L1 Expression
10.4. KRAS Mutant
11. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Non-small Cell Lung Cancer Therapeutics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Non-small Cell Lung Cancer Therapeutics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Non-small Cell Lung Cancer Therapeutics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Non-small Cell Lung Cancer Therapeutics Market
16. China Non-small Cell Lung Cancer Therapeutics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Amgen Inc.
17.6. AstraZeneca PLC
17.7. Bayer AG
17.8. BeiGene, Ltd.
17.9. Bristol-Myers Squibb Company
17.10. F. Hoffmann-La Roche Ltd.
17.11. GlaxoSmithKline plc
17.12. Merck & Co., Inc.
17.13. Novartis AG
17.14. Pfizer Inc.
17.15. Regeneron Pharmaceuticals, Inc.
17.16. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 151. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 197. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 198. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 199. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 200. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 201. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 202. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 203. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 204. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 205. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 206. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 207. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 208. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 222. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 226. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 228. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 229. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 230. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 231. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 232. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 233. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 234. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 235. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 236. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 239. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 240. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 241. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 242. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 243. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 244. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 245. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 248. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 249. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 250. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 252. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 253. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 254. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 255. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 256. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 257. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 258. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 259. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2032 (USD MILLION)
TABLE 260. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 261. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 262. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 263. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
TABLE 264. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
TABLE 265. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 266. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 267. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 268. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 269. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 270. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 271. GCC NON-SM

Companies Mentioned

The key companies profiled in this Non-small Cell Lung Cancer Therapeutics market report include:
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 38.26 Billion
Forecasted Market Value ( USD ) by 2032 $ 67.13 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report - Product Image

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Non-Small Cell Lung Cancer Pipeline Analysis Report 2025 - Product Image

Non-Small Cell Lung Cancer Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Non-Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035 - Product Image

Non-Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From

About the Non Small Cell Lung Cancer Drug Market

The Non Small Cell Lung Cancer Drug market is a subset of the larger Lung Cancer Drug market. Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is typically treated with chemotherapy, radiation, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to healthy cells. The Non Small Cell Lung Cancer Drug market is highly competitive, with a number of companies offering various treatments. Companies such as AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer are some of the major players in the market. Other companies such as Amgen, Boehringer Ingelheim, and Novartis are also active in the market. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.